Neo Ivy Capital Management Purchases 58,869 Shares of Vaxcyte, Inc. $PCVX

Neo Ivy Capital Management lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 242.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 83,110 shares of the company’s stock after buying an additional 58,869 shares during the quarter. Neo Ivy Capital Management’s holdings in Vaxcyte were worth $2,994,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Aster Capital Management DIFC Ltd acquired a new position in Vaxcyte in the 3rd quarter valued at $45,000. Virtus Investment Advisers LLC raised its holdings in Vaxcyte by 45.8% in the 2nd quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock worth $89,000 after acquiring an additional 857 shares during the period. CWM LLC lifted its position in Vaxcyte by 55.1% during the 3rd quarter. CWM LLC now owns 2,606 shares of the company’s stock worth $94,000 after acquiring an additional 926 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in Vaxcyte by 96.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock worth $117,000 after acquiring an additional 1,596 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its holdings in Vaxcyte by 110.8% during the second quarter. Osaic Holdings Inc. now owns 3,859 shares of the company’s stock valued at $128,000 after acquiring an additional 2,028 shares during the period. 96.78% of the stock is owned by institutional investors.

Vaxcyte Trading Up 1.8%

Shares of PCVX opened at $59.29 on Friday. The stock has a market cap of $8.53 billion, a PE ratio of -10.55 and a beta of 1.31. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $76.61. The stock has a 50 day simple moving average of $52.98 and a 200-day simple moving average of $44.91.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same quarter last year, the business earned ($1.12) earnings per share. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PCVX shares. Needham & Company LLC raised their price target on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. BTIG Research boosted their price objective on Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Leerink Partners set a $77.00 target price on Vaxcyte and gave the company an “outperform” rating in a report on Wednesday, November 19th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $116.00 price target on shares of Vaxcyte in a research report on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $94.50.

Insiders Place Their Bets

In related news, insider Harpreet S. Dhaliwal sold 9,743 shares of the stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the sale, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This trade represents a 28.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Elvia Cowan sold 11,623 shares of the stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total transaction of $556,974.16. Following the sale, the senior vice president owned 14,534 shares of the company’s stock, valued at $696,469.28. This trade represents a 44.44% decrease in their position. The SEC filing for this sale provides additional information. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.